Huron Consulting Group (NASDAQ: HURN), a leading provider of business consulting services, today announced a strategic alliance with Forte Research Systems, a leading provider of enterprise research software, to enhance joint offerings to research institutions.
Huron Consulting Group (NASDAQ: HURN), a leading provider of business consulting services, today announced a strategic alliance with Forte Research Systems, a leading provider of enterprise research software, to enhance joint offerings to research institutions. The Huron-Forte alliance is the result of a shared commitment to offer impactful consulting services and effective software solutions to the research industry to provide clients the following:
“The Huron-Forte alliance allows both organizations to provide greater value to our shared clients,” said Rick Rohrbach, managing director, Huron Consulting Group. “Huron can help clients transform their clinical research business processes using Forte’s OnCore. Huron will help Forte customers optimize the implementation of OnCore and other Forte software solutions to improve their return on investment. Most importantly, the interfaces between our systems will provide customers a seamless and effective research administration solution.”
“The Huron-Forte relationship will help clients gain greater efficiency with their clinical trials portfolio. With increasing enterprise-wide implementations and adoption of OnCore, Huron brings the required experience in operational and implementation planning to serve a growing need,” said Srini Kalluri, president and chief executive officer, Forte Research Systems. “Existing and new OnCore clients will also be able to take advantage of a planned standards-based interface between Huron’s Click IRB and OnCore application, which will further enhance researcher productivity. Through this alliance, we are building on past success in working closely together to broadly address customer needs. The people and approaches on both sides are aligned well for taking this important step together.”
The Huron-Forte alliance aims to increase researcher productivity and improve compliance oversight through tight integration of the two companies’ products and services. Huron will expand its ability to provide clinical trials solutions beyond its current highly configurable Click Portal. At the same time, Forte gains a deployment partner with significant industry expertise and scale to accelerate the market adoption of their leading OnCore product, which includes CTMS, electronic data capture, and biospecimen management functionality.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.